Gamida Cell
Gamida Cell Provides Key Program Updates and 2022 Financial Guidance
- Form
- 8-K
- Filed
- Period
- Importance
- Major
- Accession
- 0001213900-22-004376
- Document
- 8-K
- Announces exit or restructuring costs (2.05)
- Discloses other events (8.01)
Not explained yet; the original is on EDGAR.
Similar companies
Same SIC code (2836) and public float not reported.
- Adaptimmune Therapeutics ADAP
- Adverum Biotechnologies ADVM
- AgomAb Therapeutics AGMB
- Alvotech ALVO
- Argenx ARGX
